

EudraCT	Lægemiddelstyrelse godkendelse	Videnskabetisk godkendelse	Status	Forsøgs-lægemidler	Betegnelse	Forsøgstitel	Sponsor	Koordinerende hospital i DK	Trial sites i DK	Indikation
2020-001052-18	22. marts 2020	25. marts 2020	Godkendt	Remdesivir, placebo	INSIGHT	A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European Union/United Kingdom Sites	Regents of the University of Minnesota, US	Rigshospitalet	9 afdelinger	Behandling af COVID-19 hos hospitaliserede voksne
2020-001154-22	27. marts 2020	06. april 2020	Godkendt	Tocilizumab, Placebo	WA42380 /Version 1	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia	Roche	Hvidovre Hospital	4 afdelinger	Hospitaliserede patienter med alvorlig COVID-19 pneumoni
2020-001172-15	26. marts 2020	03. april 2020	Godkendt	APN01 (kendt som GSK2586881)	APN01-01-COVID19	Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19	APEIRON Respiratory Therapies GmbH	Rigshospitalet	2 afdelinger	Behandling af patienter med COVID-19
2020-001198-55	24. marts 2020	03. april 2020	Godkendt	Hydroxychloroquin, azithromycin, placebo	ProBe-COVID-Trial	Pro-aktiv Beskyttelse af Indlagte Patienter med COVID-19	Jens-Ulrik Stæhr Jensen, Gentofte Hospital	Gentofte Hospital	7 afdelinger	Pro-aktiv Beskyttelse af Indlagte Patienter med COVID-19
2020-001200-42	27. marts 2020	30. marts 2020	Godkendt	Camostat mesilate	Camaco-19-001	The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase I/IIa trial	Lars Østergaard, inf.sygdomme, Aarhus Universitetshospital	Aarhus Universitetshospital	9 afdelinger	Effekt på varigheden og sværhedsgraden af COVID-19
2020-001257-51	27. marts 2020	15. april 2020	Godkendt	Hydroxychloroquine	Pre-HCQ Dialysis Study	The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for prevention of COVID19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical trial	Nicholas Carlson, Rigshospitalet	Rigshospitalet	3 afdelinger	Forebyggelse af COVID19 i dialyse-behandlede patienter
2020-001270-29	03. april 2020	07. april 2020	Godkendt	Hydroxychloroquine	EFC16858	An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19.	Sanofi	Hvidovre Hospital	1 afdeling	Indlagte patienter med moderat til svær COVID-19
2020-001275-32	27. marts 2020	03. april 2020	Godkendt	Tocilizumab, Sarilumab	APPI2-CV-2020-01	Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial	The Parker Institute, DK	Bispebjerg Hospital	1 afdeling	COVID-19 patienter med alvorlig forværring i vejtrækningen
2020-001296-33	29. april 2020	06. maj 2020	Godkendt	Ilomedin (iloprost)	COMBAT-COVID-19	Effekt og sikkerhed af 72 timers infusion af Iloprost (1 ng/kg/min) til patienter med COVID-19 induceret respiratorisk endotheliotpati – et multi-center, randomiseret, placebo kontrolleret, dobbelt-blindet investigator initieret klinisk forsøg.	Pår Ingemar Johansson, Københavns Universitetshospital	Rigshospitalet	5 afdelinger	Respiratorindlagte COVID-19 patienter.
2020-001363-85	17. april 2020	23. april 2020	Godkendt	Hydroxychloroquine		COVID-19 Prophylaxis with hydroxychloroquine, vitamin D, and zinc supplementation in Danish nursing home residents – a randomized controlled trial	Jesper Ryg, Odense Universitetshospital	Odense Universitetshospital	1 afdeling	Forebyggelse af Coronavirus hos plejehjemsboere
2020-001367-88	08. april 2020	14. april 2020	Godkendt	Hydroxychloroquine, baricitinib og sarilumab. Desuden convalescent plasma (ikke lægemiddel)	CCAP-RCT	Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform	Thomas Benfield, Hvidovre Hospital	Hvidovre Hospital	12 afdelinger	Effekt og sikkerhed ved nye behandlingsmuligheder for voksne med COVID-19 pneumoni
2020-001395-15	06. april 2020	05. april 2020	Godkendt	Hydrokortison	COVID STEROID	Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia – the COVID STEROID Trial	Anders Perner, Rigshospitalet, intensiv afd.	Rigshospitalet	20 afdelinger	Patienter med COVID-19 og svær iltmangel (behov for højt ilttilskud eller respirator)
2020-001420-34	11. april 2020	14. april 2020	Godkendt	Senicapoc	COVIPOC	Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial (COVIPOC).	Ulf Simonsen, Aarhus Universitet	Aarhus Universitetshospital	3 afdelinger	COVID-19 patienter med svær respiratorisk insufficiens
2020-001459-42	21. april 2020	17. april 2020	Godkendt	Ruxolitinib		Ruxolitinib i behandlingen af svær COVID-19 infektion. Et Dansk Effekt- og Sikkerhedsstudie.	Hans Hasselbalch	Sjællands Universitetshospital	1 afdeling	Nydiagnostiserede patienter med svær COVID 19 infektion, som kræver mekanisk ventilation (respiratorhjælp) eller patienter, som har et truende behov for respiratorstøtte.

EudraCT	Lægemiddelstyrelse godkendelse	Videnskabetisk godkendelse	Status	Forsøgslægemidler	Betegnelse	Forsøgstitel	Sponsor	Koordinerende hospital i DK	Trial sites i DK	Indikation
2020-001544-26	22. april 2020	17. april 2020	Godkendt	ACE-hæmmere (captopril, enalapril, lisinopril, perindopril, ramipril, trandolapril) og angiotensin II receptor hæmmere (candesartancilexetil, irbesartan, losartan, telmisartan, olmesartan-medoxomil, valsartan)	RASCOVID-19	Effects of discontinuing renin-angiotensin system inhibitors in patients with COVID-19 (RASCOVID-19)	Filip Krag Knop, Gentofte Hospital	Gentofte Hospital	2 afdelinger	ACE-hæmmere og angiotensin-II-receptorantagonisters påvirkning af COVID-19 forløb
2020-001610-38	15. maj 2020	23. juli 2020	Godkendt	Aprovel (irbesartan) og Tamiflu (oseltamivir)	JAGG2020-1	Irbesartan and Oseltamivir treatment of COVID-19 infection.	Slagelse Sygehus, Gitte Fornitz	Slagelse Sygehus	1 afdeling	Let, moderat og svær SARS-CoV-2 sygdom.
2020-001888-90	27. april 2020	30. april 2020	Godkendt	BCG Vaccine	BCG-DENMARK-COVID	Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multicenter trial.	Christine Stabell Benn, Syddansk Universitet	Odense Universitetshospital	7 afdelinger	Immun aktivering efter BCG vaccination hos raske frivillige, sundhedspersonale
2020-001793-30	1. juli 2020	1. juli 2020	Godkendt	Benferol (vitamin D), placebo	COVIT-D	Preventing Disease Aggravation in COVID-19 by high dose Vitamin D: a randomized trial (COVIT-D)	Bispebjerg Hospital, Ahmad Sajadieh	Bispebjerg Hospital	5 afdelinger	Behandling af SARS-CoV-2 positiv testede.
2020-001870-32	18. maj 2020	20. maj 2020	Godkendt	DFV890	CDVF890D12201	Phase 2, randomized, controlled, open label multi-center study to assess efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function	Novartis	Hvidovre Hospital	3 afdelinger	SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function
2020-002049-40	18. juni 2020	26. juni 2020	Godkendt	UNI911 INHALATION	UNI911-101	Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of a Single Ascending Dose of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults with COVID-19	UNION Therapeutics	Dantrials Fase I enhed	1 afdeling	Raske forsøgspersoner (First in Human forsøg)
2020-003363-25	22. juli 2020	20. august 2020	Godkendt	Dexavit, placebo	the COVID STEROID 2 trial	Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial	Anders Perner, Rigshospitalet, intensiv afd.	Rigshospitalet	19 afdelinger	Patients with COVID-19 and Severe Hypoxia
2020-003904-15	26. august 2020	26. august 2020	Godkendt	BCG Vaccine, placebo	BCG-DENMARK-SENIOR	Using BCG vaccine to enhance non-specific protection of senior citizens during the COVID-19 pandemic. A randomized clinical trial	Christine Stabell Benn, Odense Hospital.	Odense Universitetshospital	1 afdeling	Forbyggende til +65 årige.
2020-003278-37	04. september 2020	28. august 2020	Godkendt	LY3819253	INSIGHT-014-ACTIV-3	A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19	Regents of the University of Minnesota, US	Rigshospitalet	9 afdelinger	Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19.
2020-002542-16	05. november 2020	10. november 2020	Godkendt	Anti-COVID-19 hVIG	INSIGHT-013-ITAC	An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19	Regents of the University of Minnesota, US	Rigshospitalet	10 afdelinger	Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19.
2020-006003-42	21. december 2020	30. december 2020	Godkendt	Godkendte Sars-COV-2 vacciner	ENFORCE	National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)	Jens Lundgren, Rigshospitalet	Aarhus Universitetshospital	5 afdelinger	Vaccination til forebyggelse af Sars-COV-2
2020-002322-85	01. februar 2021	25. januar 2021	Godkendt	KAND567	KAN0006	KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics.	Kancera AB (Sverige)	Odense Universitetshospital	2 afdelinger	Subjects hospitalized for COVID-19
2020-002913-16	17. december 2020	02. februar 2021	Godkendt	Alteplase	TRISTARDS	The TRISTARDS trial - Thrombolysis Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of daily intravenous alteplase treatment given up to 5 days on top of standard of care (SOC) compared with SOC alone, in patients with acute respiratory distress syndrome (ARDS) triggered by COVID-19.	Boehringer Ingelheim B.V., NL	Hvidovre Hospital	4 afdelinger	COVID-19 patients with ARDS, either on non-invasive ventilator support, OR on mechanical ventilation.

Opdateret den 17. februar 2021